Press release
Alzheimer's Disease - Drug Pipeline Landscape, 2022 | ADRx Inc, Aerobyx LLC, AIBIOS Co Ltd, Akome Biotech Ltd
Alzheimer's Disease
Alzheimer's disease is a progressive, degenerative brain disorder that attacks the brain's nerve cells, or neurons, and causes them to waste away. This disease is characterized by a slow, gradual decline in memory, thinking, and reasoning skills. Alzheimer's is the most common form of dementia, accounting for 60 to 80 percent of all cases. Dementia is a general term for a decline in mental ability severe enough to interfere with daily life.
View Detailed Report Description : https://www.globalinsightservices.com/reports/alzheimers-disease-drug-pipeline-landscape-2022/
Alzheimer's disease is named after German physician Alois Alzheimer. In 1906, Dr. Alzheimer noticed changes in the brain tissue of a patient who had died of an unusual mental illness. He found abnormal clumps (now called amyloid plaques) and tangled bundles of fibers (now called neurofibrillary tangles) among the patient's brain cells. These discoveries provide some of the first hints about what happens in the brains of people with Alzheimer's.
Scientists now know that the plaques and tangles are made up of specific proteins that build up in and around brain cells. These proteins damage and kill brain cells. As more brain cells die, connections among cells are lost. This process starts slowly, but over time, it spreads throughout the brain.
Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. The disease severely affects memory, thinking, learning and organizing skills and eventually affects a person's ability to carry out simple daily activities.
The exact cause of Alzheimer's is unknown but there are certain risk factors like age, family history, genetics, depression, smoking and cardiovascular disease.
Request Sample Report : https://www.globalinsightservices.com/request-sample/GIS31031
Report Highlights
Global Insight Service's, Alzheimer's Disease - Drug Pipeline Landscape, 2022 report provides an overview of the Alzheimer's Disease pipeline drugs. This report covers detailed insights on Alzheimer's Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Alzheimer's Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Purchase your copy now : https://www.globalinsightservices.com/checkout/single_user/GIS31031
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Key Players
• 1st Bio Therapeutics Inc
• 2A Pharma AB
• AB Science
• AbbVie
• Abyssinia Biologics LLC
• AC Immune SA
• Accuitis Pharmaceuticals Inc
• Acelot Inc
• Actinogen Medical Ltd
• Acumen Pharmaceuticals
• ADRx Inc
• Aerobyx LLC
• AIBIOS Co Ltd
• Akome Biotech Ltd
• Alchemab Therapeutics Ltd
• Alector Inc
• Alkahest, Inc.
• Allyx Therapeutics
• Alnylam Pharmaceuticals
Request For Customization : https://www.globalinsightservices.com/request-customization/GIS31031
Reasons to buy Alzheimer's Disease Report:
• Develop comprehensive understanding of market landscape - industry structure, value-chain, key players, trends, drivers, and challenges
• Drive revenue and market-entry strategy by gaining insights into which segments and geographies are largest and likely to grow fastest
• Formulate sales and marketing strategies by gaining understanding of competitors, their positioning, and strengths & weaknesses
• Develop business and M&A strategies through understanding of latest trends and emerging players in the market
• Refine your business plans by understanding impact of disruptions such as Covid-19 and Russia-Ukraine conflict on the market
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease - Drug Pipeline Landscape, 2022 | ADRx Inc, Aerobyx LLC, AIBIOS Co Ltd, Akome Biotech Ltd here
News-ID: 2796406 • Views: …
More Releases from Global Insight Services
Handmade Jewelry Market Expected to Grow from $203.8 Billion in 2024 to $594.3 B …
The Handmade Jewelry Market has emerged as a vibrant and fast-growing sector, driven by the rising consumer preference for artisanal, personalized, and ethically produced accessories. Handmade jewelry encompasses a wide array of products, including necklaces, bracelets, earrings, rings, and other unique adornments, often crafted using precious metals, gemstones, and innovative materials. Unlike mass-produced jewelry, handmade pieces resonate with consumers seeking individuality, sustainability, and artistic expression. The market benefits greatly from…
Gene Silencing Market Expected to Grow from $4.66 Billion in 2024 to $11.31 Bill …
The Gene Silencing Market is emerging as one of the most promising areas in biotechnology and medical research. By using advanced tools to suppress gene expression, scientists can better understand genetic functions and design treatments for diseases at their roots. Techniques such as RNA interference (RNAi), antisense oligonucleotides, and CRISPR-based approaches have broadened the scope of applications, from therapeutic innovations to agricultural advancements. This market not only reflects the cutting…
Risk Management Software Market Is Anticipated To Expand From $14.9 Billion In 2 …
Market Overview
The Risk Management Software Market is becoming an essential pillar for organizations across industries as they navigate an increasingly complex business environment. Companies face rising challenges ranging from regulatory compliance and cybersecurity threats to operational inefficiencies and supply chain disruptions. Risk management software provides a unified solution to identify, monitor, and mitigate these risks, enabling organizations to make informed decisions while safeguarding business continuity. These tools are not limited…
Rare Disease Treatment Market Expected to Grow from $213.5 Billion in 2024 to $5 …
The Rare Disease Treatment Market is emerging as one of the most dynamic sectors in the global healthcare landscape. This market focuses on the development, production, and distribution of therapies designed to address rare and complex medical conditions affecting a small percentage of the population. Rare diseases, often genetic in origin, pose significant treatment challenges, which has prompted biopharmaceutical companies to invest in innovative solutions such as orphan drugs, gene…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
